Characterisation of tumour heterogeneity and identification of adaptive resistance mechanisms of metastatic castration-resistant prostate carcinoma
Recruiting
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00028021
- Lead Sponsor
- Klinik für Nuklearmedizin am Universitätsklinikum Augsburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 45
Inclusion Criteria
Patients between 18 and 99 years of age
- Fulfilment of the standard criteria for a 177Lu-PSMA RLT
- Low-risk accessibility of a PSMA-positive lesion by percutaneous biopsy
Exclusion Criteria
- Persons who are placed in an institution by court order or by order of the authorities.
- Persons who are in a dependent relationship or employment relationship with the sponsor or investigator.
- Severe psychiatric illnesses
- Patients with congenital bleeding disorders (e.g. von Willebrand disease).
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A. Is it possible to map intratumoural heterogeneity of metastatic castration-resistant prostate carcinoma based on different metabolic activity in positron emission tomography (PET) (cohort A)?<br>B. Can adaptive resistance mechanisms of metastatic castration-resistant prostate cancer be identified from metastatic biopsies before and after 177Lu-PSMA-RLT (Cohort B)?
- Secondary Outcome Measures
Name Time Method Can tumour-specific mutations in circulating cell-free DNA (ctDNA) be detected as plasma markers?